Ecuador to pay royalties on pharma patents
More details have emerged about Ecuador’s declaration that it will allow local firms to manufacture patented medicines under compulsory licence, in order to reduce their prices.
Read MoreAuthor: Lynne Taylor
US House health bill “could cost pharma $150 billion”
The US House of Representatives could vote later this week on its controversial health reform bill, which analysts say could cost drugmakers as much as $150 billion over a decade.
Read MoreIndustry/university deals “critical to US economy”
In terms of product sales, licensing agreements between universities and companies contributed as much as $187 billion to US Gross Domestic Product (GDP) during 1996-2007, according to new estimates.
Read MoreUS FDA slammed over post-marketing studies
The US Food and Drug Administration (FDA) fast-track approval process for drugs to treat serious and life-threatening conditions requires makers to conduct post-marketing studies on their products, but a new study has found that some such studies have still not been completed more than eight years after the drugs were approved for marketing.
Read MoreGovt to reveal NHS spending on management consultants
Starting next summer, the Department of Health will publish details of how much NHS organisations spend per year on management consultants, the government announced late last week.
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
